Highlights Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
39.7 ^CNY	-1.49%		-1.93%	+13.40%

05-14	Livzon Pharmaceutical Group Cancels Share Options	MT
05-14	Livzon Pharmaceutical Declares Final Dividend for 2023	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Livzon Pharmaceutical Declares Final Dividend for 2023	05-14	MT
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	04-26	CI
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	04-24	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	04-02	CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	03-29	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	03-28	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	02-23	MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	02-22	CI
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	01-18	CI
Livzon Pharma Recognizes Credit, Asset Impairments	01-10	MT
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	12-19	MT
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	12-14	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	12-04	MT
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	12-03	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng.	11-20	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin.	11-20	CI
Livzon Pharma Boosts Stake in Diagnostic Equipment Unit Ahead of Spinoff	11-20	MT
Livzon Pharmaceutical Group Inc. entered into share purchase agreement to acquire an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin for CNY 24.57 million.	11-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Livzon Pharmaceutical Group Inc.

Equities

000513

CNE0000002Y8

Highlights

Filters